Withdrawn trial sought clues in breast Cancer's immune environment
NCT ID NCT06710197
Summary
This withdrawn study aimed to learn how a 14-day course of an immune-modulating drug (Anakinra) changes the area immediately surrounding early-stage breast cancer tumors. It planned to enroll patients with small, early tumors who were not scheduled for chemotherapy before surgery. The goal was to compare tissue samples taken before and after the short drug treatment to understand its biological effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY STAGE TRIPLE NEGATIVE ER LOW BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Health Network-Princess Margaret Cancer Center
Toronto, Ontario, M5G 2M9, Canada
Conditions
Explore the condition pages connected to this study.